FDA Approves Edwards Lifesciences Pascal Precision System
The device provides a new transcatheter treatment option for patients diagnosed with severe tricuspid regurgitation.
Updated on Oct. 21, 2026 in Heart Disease
Live Poll
Do you believe new medical technology typically leads to better health outcomes for patients?
The FDA has granted approval for the Edwards Lifesciences Pascal Precision system to treat severe tricuspid regurgitation. The device is designed to hold valve leaflets together to ensure a tighter seal and improved valve function.
Why it matters
This approval marks a significant expansion in treatment options for patients with complex valve conditions. Edwards Lifesciences is now the only U.S. manufacturer offering both transcatheter edge-to-edge repair and replacement therapies for both mitral and tricuspid valves.
The Pascal Precision system, which received mitral regurgitation approval in 2022, allows surgeons to independently grasp and reposition valve leaflets before final closure.
The players
Edwards Lifesciences
This global medical technology company specializes in products for structural heart disease and critical care monitoring.
Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of medical devices in the United States.
The details
The device is delivered through the femoral artery to address the tricuspid valve leaflets directly. The FDA also approved the Pascal Ace clip implant for mitral repair, which features the Capture Clarity system for enhanced fluoroscopic visualization.
Timeline
The Pascal Precision system received approval for mitral regurgitation in 2022.
Clinical data regarding the system is scheduled for presentation from October 31 to November 3, 2026.
The Sapien M3 is scheduled for anticipated valve replacement approval in late 2025.
The Big Picture
This development follows the regulatory standards established by the FDA's existing medical device authorization pathways. The move reinforces the company's competitive position in the transcatheter structural heart market.
Patients with severe tricuspid regurgitation may now have access to a less invasive, transcatheter-based repair option compared to traditional surgical interventions. This allows for potential improvements in heart function and quality of life for those eligible for this therapy.
The takeaway
This approval represents a shift toward minimally invasive options for complex heart valve disease. Patients should consult with their cardiologists to determine if transcatheter edge-to-edge repair is a viable treatment option for their specific medical history.
What happens next
Edwards Lifesciences plans to present clinical trial data for the Pascal Precision system at the Transcatheter Cardiovascular Therapeutics conference, which takes place in San Diego from October 31 to November 3, 2026.
Further reading
For more information on current treatment trends, visit the Heart Disease section.
Live Poll
Do you believe new medical technology typically leads to better health outcomes for patients?
